<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, there have been various approaches to address ACE2-mediated SARS-CoV-2 entry. A therapeutic strategy to be taken into consideration is to prevent the virus/ACE2 attachment through mAbs specifically designed against specific epitopes of the S protein, especially the RBD-S1 unit (
 <xref rid="B92" ref-type="bibr">Sui et al., 2004</xref>; 
 <xref rid="B28" ref-type="bibr">Elshabrawy et al., 2012</xref>). This unit shares a relatively high homology (73%) between SARS-CoV-2 and SARS-CoV, allowing the identification of cross reactive antibodies 
 <italic>in vitro</italic> or in animal models (
 <xref rid="B94" ref-type="bibr">Tian et al., 2020</xref>).
</p>
